151 results on '"Baraldi, E."'
Search Results
2. RSV Prevention in All Infants: Which Is the Most Preferable Strategy?
- Author
-
Esposito, S. Abu Raya, B. Baraldi, E. Flanagan, K. Martinon Torres, F. Tsolia, M. Zielen, S.
- Abstract
Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses in infants and young children that may lead to hospitalizations and a substantial number of outpatient visits, which result in a huge economic and healthcare burden. Most hospitalizations happen in otherwise healthy infants, highlighting the need to protect all infants against RSV. Moreover, there is evidence on the association between early-life RSV respiratory illness and recurrent wheezing/asthma-like symptoms As such, RSV is considered a global health priority. However, despite this, the only prevention strategy currently available is palivizumab, a monoclonal antibody (mAb) indicated in a subset of preterm infants or those with comorbidities, hence leaving the majority of the infant population unprotected against this virus. Therefore, development of prevention strategies against RSV for all infants entering their first RSV season constitutes a large unmet medical need. The aim of this review is to explore different immunization approaches to protect all infants against RSV. Prevention strategies include maternal immunization, immunization of infants with vaccines, immunization of infants with licensed mAbs (palivizumab), and immunization of infants with long-acting mAbs (e.g., nirsevimab, MK-1654). Of these, palivizumab use is restricted to a small population of infants and does not offer a solution for all-infant protection, whereas vaccine development in infants has encountered various challenges, including the immaturity of the infant immune system, highlighting that future pediatric vaccines will most likely be used in older infants (>6 months of age) and children. Consequently, maternal immunization and immunization of infants with long-acting mAbs represent the two feasible strategies for protection of all infants against RSV. Here, we present considerations regarding these two strategies covering key areas which include mechanism of action, "consistency" of protection, RSV variability, duration of protection, flexibility and optimal timing of immunization, benefit for the mother, programmatic implementation, and acceptance of each strategy by key stakeholders. We conclude that, based on current data, immunization of infants with long-acting mAbs might represent the most effective approach for protecting all infants entering their first RSV season. Copyright © 2022 Esposito, Abu Raya, Baraldi, Flanagan, Martinon Torres, Tsolia and Zielen.
- Published
- 2022
3. New strategies for Botrytis bunch rot control for a sustainable viticulture
- Author
-
Lagreze Perez, J., Brescia, M., Baraldi, E., Prati, R., Moser, C., and Malacarne, G.
- Subjects
Botrytis cinerea ,Settore AGR/07 - GENETICA AGRARIA ,Bunch rot ,Management protocols ,Molecular assay ,Grapevine ,Sustainable viticulture ,Integrated defence - Published
- 2022
4. Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial
- Author
-
Hill, LF, Clements, MN, Turner, MA, Donà, D, Lutsar, I, Jacqz-Aigrain, E, Heath, PT, Roilides, E, Rawcliffe, L, Alonso-Diaz, C, Baraldi, E, Dotta, A, Ilmoja, M-L, Mahaveer, A, Metsvaht, T, Mitsiakos, G, Papaevangelou, V, Sarafidis, K, Walker, AS, Sharland, M, and NeoVanc Consortium
- Abstract
BACKGROUND: Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to assess optimised vancomycin dosing. We compared the efficacy of an optimised regimen to a standard regimen in infants with late onset sepsis that was known or suspected to be caused by Gram-positive microorganisms. METHODS: NeoVanc was an open-label, multicentre, phase 2b, parallel-group, randomised, non-inferiority trial comparing the efficacy and toxicity of an optimised regimen of vancomycin to a standard regimen in infants aged 90 days or younger. Infants with at least three clinical or laboratory sepsis criteria or confirmed Gram-positive sepsis with at least one clinical or laboratory criterion were enrolled from 22 neonatal intensive care units in Greece, Italy, Estonia, Spain, and the UK. Infants were randomly assigned (1:1) to either the optimised regimen (25 mg/kg loading dose, followed by 15 mg/kg every 12 h or 8 h dependent on postmenstrual age, for 5 ± 1 days) or the standard regimen (no loading dose; 15 mg/kg every 24 h, 12 h, or 8 h dependent on postmenstrual age for 10 ± 2 days). Vancomycin was administered intravenously via 60 min infusion. Group allocation was not masked to local investigators or parents. The primary endpoint was success at the test of cure visit (10 ± 1 days after the end of actual vancomycin therapy) in the per-protocol population, where success was defined as the participant being alive at the test of cure visit, having a successful outcome at the end of actual vancomycin therapy, and not having a clinically or microbiologically significant relapse or new infection requiring antistaphylococcal antibiotics for more than 24 h within 10 days of the end of actual vancomycin therapy. The non-inferiority margin was -10%. Safety was assessed in the intention-to-treat population. This trial is registered at ClinicalTrials.gov (NCT02790996). FINDINGS: Between March 3, 2017, and July 29, 2019, 242 infants were randomly assigned to the standard regimen group (n=122) or the optimised regimen group (n=120). Primary outcome data in the per-protocol population were available for 90 infants in the optimised group and 92 in the standard group. 64 (71%) of 90 infants in the optimised group and 73 (79%) of 92 in the standard group had success at test of cure visit; non-inferiority was not confirmed (adjusted risk difference -7% [95% CI -15 to 2]). Incomplete resolution of clinical or laboratory signs after 5 ± 1 days of vancomycin therapy was the main factor contributing to clinical failure in the optimised group. Abnormal hearing test results were recorded in 25 (30%) of 84 infants in the optimised group and 12 (15%) of 79 in the standard group (adjusted risk ratio 1·96 [95% CI 1·07 to 3·59], p=0·030). There were six vancomycin-related adverse events in the optimised group (one serious adverse event) and four in the standard group (two serious adverse events). 11 infants in the intention-to-treat population died (six [6%] of 102 infants in the optimised group and five [5%] of 98 in the standard group). INTERPRETATION: In the largest neonatal vancomycin efficacy trial yet conducted, no clear clinical impact of a shorter duration of treatment with a loading dose was demonstrated. The use of the optimised regimen cannot be recommended because a potential hearing safety signal was identified; long-term follow-up is being done. These results emphasise the importance of robust clinical safety assessments of novel antibiotic dosing regimens in infants. FUNDING: EU Seventh Framework Programme for research, technological development and demonstration.
- Published
- 2022
5. Complete Genome Sequence of the Plant-Pathogenic Fungus Colletotrichum lupini
- Author
-
Baroncelli R., Pensec F., Lio D. D., Boufleur T., Vicente I., Sarrocco S., Picot A., Baraldi E., Sukno S., Thon M., Le Floch G., Baroncelli R., Pensec F., Lio D.D., Boufleur T., Vicente I., Sarrocco S., Picot A., Baraldi E., Sukno S., Thon M., and Le Floch G.
- Subjects
Lupinus sp ,fungi ,Plant Disease ,food and beverages ,SMRT sequencing ,Complete genome ,Ascomycota ,Fungus-plant interaction ,Comparative genomic ,Genome, Mitochondrial ,Genomic ,Colletotrichum ,Anthracnose ,Genome, Fungal - Abstract
Colletotrichum is a fungal genus (Ascomycota, Sordariomycetes, Glomerellaceae) that includes many economically important plant pathogens that cause devastating diseases of a wide range of plants. In this work, using a combination of long- and short-read sequencing technologies, we sequenced the genome of Colletotrichum lupini RB221, isolated from white lupin (Lupinus albus) in France during a survey in 2014. The genome was assembled into 11 nuclear chromosomes and a mitochondrial genome with a total assembly size of 63.41 Mb and 36.55 kb, respectively. In total, 18,324 protein-encoding genes have been predicted, of which only 39 are specific to C. lupini. This resource will provide insight into pathogenicity factors and will help provide a better understanding of the evolution and genome structure of this important plant pathogen.
- Published
- 2021
6. Trends in neonatal emergency transport in the last two decades
- Author
-
Trevisanuto, D., Cavallin, F., Loddo, C., Brombin, L., Lolli, E., Doglioni, N., Baraldi, E., Cavicchiolo, M. E., Mardegan, V., Magarotto, M., Nardo, D., Piva, D., Priante, E., and Salvadori, S.
- Subjects
medicine.medical_specialty ,Joinpoint regression ,medicine.medical_treatment ,Transport ,Intermittent Positive-Pressure Ventilation ,03 medical and health sciences ,0302 clinical medicine ,Neonate ,Pregnancy ,030225 pediatrics ,medicine ,Respiratory management ,Trend ,Humans ,In patient ,030212 general & internal medicine ,Respiratory system ,Mechanical ventilation ,Respiratory Distress Syndrome, Newborn ,Emergency transport ,Continuous Positive Airway Pressure ,business.industry ,Infant, Newborn ,Infant ,Large series ,Respiration, Artificial ,Care facility ,Pediatrics, Perinatology and Child Health ,Emergency medicine ,Female ,business ,Infant, Premature - Abstract
Although maternal antenatal transfer is the preferred option, some infants inevitably need urgent transport to a tertiary neonatal care facility after birth. This study aimed to investigate trends over time in patient characteristics and respiratory management in a large series of neonatal emergency transfers, in order to provide health caregivers an up-to-date profile of such patients and their therapeutic needs. Trends in patient characteristics and respiratory management were evaluated in 3337 transfers by the Eastern Veneto Neonatal Emergency Transport Service in 2000–2019. Joinpoint regression analysis was performed to evaluate trends and to estimate annual percentage changes (APCs). Proportions of preterm neonates increased (APC2000–2012 2.25%), then decreased (APC2012–2019 − 6.04%). Transfers at birth increased (APC2000–2013 2.69%), then decreased (APC2013–2019 − 5.76%). Proportion of neonates with cardiac and surgical diseases declined (APCs2000–2019 − 6.82% and − 3.32%), while proportion of neonates with neurologic diseases increased (APC2000–2019 8.62%). Use of nasal-continuous-positive-airway-pressure (APC2000–2019 9.72%) and high-flow-nasal-cannula (APC2007–2019 58.51%) at call, and nasal-continuous-positive-airway-pressure (APC2000–2019 13.87%) and nasal-intermittent-mandatory-ventilation (APC2000–2019 32.46%) during transfer increased. Mechanical ventilation during transfer decreased (APC2014–2019 − 10.77%). Use of oxygen concentrations at 21% increased at call and during transfer (APCs 2000–2019 2.24% and 2.44%), while oxygen concentrations above 40% decreased at call and during transfer (APCs 2000–2019 − 3.93% and − 5.12%). Conclusion: Our findings revealed a shift toward a more “gentle” approach and the reduced use of oxygen in respiratory management. Equipment and team expertise should meet the requirements of such changing patients and their therapeutic needs.
- Published
- 2021
7. Testosterone (T) is poorly related to sexual desire and Erectile Dysfunction (ED) in Young/Middle Aged Human immunodeficiency virus (HIV)-Infected Men
- Author
-
De Vincentis, S., Decaroli, M. C., Diazzi, C, Morini, F., Bertani, D., Fanelli, F., Mezzullo, M., Santi, D., Tartaro, G., Baraldi, E., Tagliavini, S., Pagotto, U., Guaraldi, G., and Rochira, V.
- Subjects
IIEF-15 ,erectile dysfunction ,sexual dysfunction ,testosterone ,HIV ,hypogonadism ,HIV, testosterone, erectile dysfunction, sexual dysfunction, IIEF-15, hypogonadism - Published
- 2020
8. Low Serum Testosterone (T) Is Associated with Poor Health Status in Young to Middle-Aged Human Immunodeficiency Virus (HIV)-Infected Men
- Author
-
De Vincentis, S., Decaroli, M. C., Diazzi, C., Morini, F., Bertani, D., Fanelli, F., Mezzullo, M., Santi, D., Tartaro, G., Baraldi, E., Tagliavini, S., Pagotto, U., Guaraldi, G., and Rochira, V.
- Subjects
AIDS ,sex steroids, mass spectrometry, AIDS, HIV, hypogonadism, testosterone, health status, comorbidities ,testosterone ,HIV ,hypogonadism ,sex steroids ,health status ,comorbidities ,mass spectrometry - Published
- 2020
9. Corrigendum to 'Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV' [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019)
- Author
-
Karampatou, A., Han, X., Kondili, L. A., Taliani, G., Ciancio, A., Morisco, F., Critelli, R. M., Baraldi, E., Bernabucci, V., Troshina, G., Guarino, M., Tagliavini, S., D'Ambrosio, F., Bristot, L., Turco, L., Rosato, S., Vella, S., Trenti, T., Neri, I., La Marca, A., Manthena, S., Goldstein, A. S., Bruno, S., Bao, Y., Gonzalez, Y. S., Villa, E., Craxi, A., Petta, S., Calvaruso, V., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Karampatou A., Han X., Kondili L.A., Taliani G., Ciancio A., Morisco F., Critelli R.M., Baraldi E., Bernabucci V., Troshina G., Guarino M., Tagliavini S., D'Ambrosio F., Bristot L., Turco L., Rosato S., Vella S., Trenti T., Neri I., La Marca A., Manthena S., Goldstein A.S., Bruno S., Bao Y., Gonzalez Y.S., Villa E., Craxi A., Petta S., Calvaruso V., Brunetto M., Coco B., Chessa L., Pasetto M.C., Bigliotti E., Tamburrini F., Montalto G., Capitano A.R., Ieluzzi D., Fattovich G., Zignego A.L., Monti M., Gragnani L., Zuin M., Finati E., Giorgini A., Angarano G., Milella M., Alessandro F., Dallio M., Mazzella G., Lazzarini G., Di Fine M., Russo F.P., Zanetto A., Castelli F., Zaltron S., Raimondo G., Filomia R., Puoti M., Danieli E., Strazzabosco M., Gemma M., Angelico M., De Leonardis F., Gori A., Cappelletti E., Bruno R., Cima S., Coppola C., Amoruso D.C., Andreone P., Simonetti G., Gaeta G.B., Brancaccio G., Toniutto P., Dissegna D., Mondelli M., Ludovisi S., Persico M., Masarone M., Torti C., Strazzulla A., Rosina F., Framarin L., Weimer L.E., Quaranta M.G., Falzano L., and Mallano A.
- Subjects
Hepatology ,Hepatitis B ,EASL guidelines ,Treatment ,Interferon ,Entecavir ,Tenofovir ,TAF ,HBsAg ,Hepatocellular carcinoma ,HBV DNA ,HBV reactivation ,Mother to child transmission ,EASL guideline - Abstract
It has come to our attention that the PITER framework investigator, Alessandro Federico, was incorrectly listed as F. Alessandro in the original manuscript. Please note that the correct name of this author is Alessandro Federico (2nd University of Naples). The correct list of PITER investigators is in the footnote below.
- Published
- 2018
10. Combination of PEF and Aureobasidium pullulans treatment on acrylamide mitigation in potato crisps
- Author
-
Genovese, J., Di Francesco, A., Tappi, S., Rocculi, P., Baraldi, E., Romani, S., and Genovese J., Di Francesco A., Tappi S., Rocculi P., Baraldi E., Romani S.
- Subjects
Aureobasidium pullulans treatment ,acrylamide ,acrylamide,PEF,Aureobasidium pullulans treatment,potato crisps ,Settore AGR/15 - Scienze e Tecnologie Alimentari ,PEF ,potato crisps - Abstract
According to the new EU Regulation (2017/2158), which has established new “mitigation measures and benchmark levels for the reduction of acrylamide in foods”, there is the necessity to adapt different process methods in order to reduce the acrylamide formation in deep-fat fried potato-based products, and at the same time to maintain the quality of final products acceptable. Among strategies suggested for the reduction of acrylamide in potato crisps, pulsed electric fields (PEF) represent a promising innovative technology with the potentiality to remove Maillard reaction substrates, such as reducing sugars and free asparagine, in raw potato tissues. Recently, it has been reported that the strain L1 of the yeast Aureobasidium pullulans has the ability to assimilate asparagine in food systems. On the basis of this consideration, the aim of the study was to evaluate the possibility of the reduction of acrylamide content in potato crisps, pre-treating the raw material using a combination of PEF treatment to enhance the extractability of asparagine and a subsequent treatment with aqueous suspension of the aforementioned yeast. Potato tubers (Solanum tuberosum, var. Lady Claire) were manually peeled and sliced and submitted to PEF pre-treatment using a lab-scale unit delivering rectangular shape pulses. An electric field strength of 1.5 kV/cm and 1000 pulses were used. Consequently, PEF-treated samples were soaked in 250 ml of L1 water suspension (108 cells/ml) for different times at 25 C. A commercial deep-fat fryer was used for the frying tests. Fried potato crisp samples were analysed for moisture, asparagine content, colour, texture, oil uptake and acrylamide content. Results showed a significant reduction of asparagine content and therefore of acrylamide formation after frying. PEF pre-treatment of raw potato slices allowed the cell de- compartmentalisation enhancing the sugars and asparagine availability and so their assimilability from yeasts.
- Published
- 2018
11. An inductive exploration of the implementation knowledge of research funders
- Author
-
Brantnell, A., Baraldi, E., and Achterberg, T. van
- Subjects
Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi ,healthcare research ,GUIDELINES ,Healthcare improvement science Radboud Institute for Health Sciences [Radboudumc 18] ,quality improvement ,Interviews as Topic ,Translational Research, Biomedical ,All institutes and research themes of the Radboud University Medical Center ,Research Support as Topic ,knowledge use ,Humans ,implementation ,Qualitative Research ,POLICY-MAKERS ,Sweden ,Science & Technology ,Research policy ,BARRIERS ,lcsh:Public aspects of medicine ,Research ,lcsh:RA1-1270 ,Health Care Service and Management, Health Policy and Services and Health Economy ,QUALITATIVE RESEARCH ,policy-maker ,SYSTEMATIC REVIEWS ,research funder ,Knowledge ,Health Care Sciences & Services ,PARTICIPATORY RESEARCH ,HEALTH-CARE ,Health Policy & Services ,EXPERIENCE ,Health Services Research ,Diffusion of Innovation ,TRANSLATION ,Life Sciences & Biomedicine ,BEHAVIOR - Abstract
Background Healthcare research funders may undertake various roles to facilitate implementation of research findings. Their ability to enact such roles depends on several factors, knowledge of implementation being one essential requirement. However, previous studies do not assess the type or level of knowledge about implementation that research funders possess. This paper therefore presents findings from a qualitative, inductive study of the implementation knowledge of research funders. Three aspects of this knowledge are explored, namely how research funders define implementation, their level of self-assessed implementation knowledge and the factors influencing their self-assessment of implementation knowledge. Methods Research funders (n = 18) were purposefully selected from a sample of research funding organisations in Sweden (n = 10). In-depth semi-structured interviews were conducted, recorded and transcribed verbatim. An inductive method using a systematic coding procedure was employed to derive the findings. Results The research funders defined implementation as either an outcome or a process, with the majority believing that implementation of healthcare research results demands a process, although its complexity varied in the research funders’ view. They perceived their own level of implementation knowledge as either limited or substantial, with a majority regarding it as limited. Clinical research experience, clinical experience and task relevance were singled out as the clearest factors affecting the self-assessment of their own implementation knowledge. Conclusions This study, the first to focus on implementation knowledge of research funders, demonstrates that they are a category of policy-makers who may possess knowledge, based on their previous professional experience, that is comparable to some important findings from implementation research. Consequently, the findings not only pinpoint the relevance of professional experience, but also reveal a lack of awareness and knowledge of the results of implementation research among research funders in charge of healthcare research. Electronic supplementary material The online version of this article (10.1186/s12961-019-0472-8) contains supplementary material, which is available to authorized users.
- Published
- 2019
12. Gonadal Function in Human Immunodeficiency Virus (HIV)-Infected Men Assessed by Isotopic Dilution-Liquid Chromatography-Tandem Mass Spectrometry (ID-LC-MS/MS) and Chemiluminescent Immunoassay
- Author
-
De Vincentis, S., Decaroli, M. C., Diazzi, C., Morini, F., Bertani, D., Fanelli, F., Mezzullo, M., Santi, D., Baraldi, E., Tagliavini, S., Pagotto, U., Guaraldi, G., and V. Rochira.
- Subjects
Chemiluminescent Immunoassay ,testosterone ,HIV ,sex steroids ,mass spectrometry, sex steroids, testosterone, HIV, ID-LC-MS/MS, Chemiluminescent Immunoassay ,ID-LC-MS/MS ,mass spectrometry - Published
- 2019
13. Multilevel approach to male infertility using machine learning
- Author
-
Santi, D, Spaggiari, G, Michelangeli, M, Casarini, L, Grassi, R, Vecchi, B, Roli, L, MC De Santis, Baraldi, E, Setti, M, Trenti, T, and Simoni., M
- Published
- 2019
14. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)
- Author
-
Benders, MJNL, Klebermass-Schrehof, K, Metsaranta, M, Rudiger, M, Poets, CF, Benders, M, Allegaert, K, Naulaers, G, Guimaraes, H, Stiris, T, Vanhatalo, S, Metsvaht, T, Engel, C, Maiwald, CA, von Oldershausen, G, Bergmann, I, Weiss, M, Wichera, CJBR, Eichhorn, A, Raubuch, M, Schuler, B, van Veldhuizen, CKW, Lameris, B, Jacobs, Y, van der Vlught-Meijer, R, Kliniken, T, Griesmaier, E, Salzburg, U, Brandner, J, Tackoen, M, Reibel, R, Cornette, L, Viellevoye, LR, Saik, P, Kaar, R, Andresson, P, Franz, AR, Carus, CG, Winkler, S, Hoehn, T, Teig, N, Schroth, M, Fusch, C, Thome, UH, Ehrhardt, H, Cattarossi, L, Mauro, I, Baraldi, E, Carnielli, V, Paterlini, MG, Napolitano, M, Faldini, F, Lista, GL, Barbarini, M, Pagani, L, Anna, S, Mastretta, E, Vento, G, Fumagalli, MM, Binotti, NM, van Weissenbruch, MM, van Straaten, HLM, Annink, KV, van Bel, F, Dudink, J, Derks, JB, de Boer, IP, Meijssen, CB, de Haan, TR, van Rooij, LG, van Hillegersberg, JL, van Dongen, M, Dassel, ACM, Dijkman, KP, van Houten, MA, van der Schoor, SRD, Nestaas, E, Mazela, J, Karpinski, L, Vilan, AI, de Pinho, LF, Ferraz, C, Pereira, A, Barroso, R, da Graca, M, Tome, T, Pinto, F, Vento, M, Rodilla, JM, Luz, M, Pico, C, Camprubi, MC, Suazo, JAH, Valverde, E, Lorenzo, JRF, Orgado, JM, Boix, H, Parrilla, FJ, Blanco, D, Moral-Pumarega, MT, Bassler, D, Maletzki, J, Knoepfli, C, Hagmann, C, Kleber, M, Schulzke, S, Stocker, M, Birkenmaier, A, Riedel, T, and ALBINO Study Grp
- Subjects
Hypothermia therapy ,Perinatal asphyxia ,Allopurinol ,Neonatal oxygen deficiency ,Hypoxic-ischemic encephalopathy ,Cerebral palsy ,Childbirth outcome ,Brain injury - Abstract
BackgroundPerinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia.MethodsThis study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age36weeks and a birth weight2500g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion.DiscussionThis trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia.Trial registrationNCT03162653, www.ClinicalTrials.gov, May 22, 2017.
- Published
- 2019
15. Effect of innovative pre-treatments on mitigation of acrylamide formation in potato chips
- Author
-
Schouten, M. A., Tappi, S., Genovese, J., Di Francesco, A., Baraldi, E., Cortese, M., Caprioli, G., Angeloni, S., Vittori, S., and S. Romani.
- Published
- 2019
16. Approccio a multilivelli all’infertilità maschile utilizzando il machine learning
- Author
-
Santi, D, Spaggiari, G, Michelangeli, M, Casarini, L, Grassi, R, Vecchi, B, Roli, L, De Santis MC, Baraldi, E, Setti, M, Trenti, T, and Simoni, M
- Published
- 2018
17. Priorities for future research into asthma diagnostic tools: A PAN-EU consensus exercise from the European asthma research innovation partnership (EARIP)
- Author
-
Garcia-Marcos, L, Edwards, J, Kennington, E, Aurora, P, Baraldi, E, Carraro, S, Gappa, M, Louis, R, Moreno-Galdo, A, Peroni, DG, Pijnenburg, M, Priftis, KN, Sanchez-Solis, M, Schuster, A, Walker, S, Blakey, J, Compton, C, Fleming, L, Fowler, S, Gaillard, E, Gibson, F, Glenn Crater, G, Niven, R, Roberts, A, Ryan, D, Seppala, U, Usmani, O, Van der Schee, M, Van Sont, J, and Pediatrics
- Subjects
medicine.medical_specialty ,Consensus ,Allergy ,diagnosis ,Immunology ,MEDLINE ,Delphi method ,Physical examination ,asthma, children, lung function, inflammation, diagnosis ,Diagnostic tools ,03 medical and health sciences ,0302 clinical medicine ,children ,medicine ,Immunology and Allergy ,Humans ,Metabolomics ,030212 general & internal medicine ,Lung function ,Asthma ,medicine.diagnostic_test ,business.industry ,Health Priorities ,Research ,lung function ,medicine.disease ,Prognosis ,respiratory tract diseases ,Respiratory Function Tests ,Europe ,030228 respiratory system ,1117 Public Health And Health Services ,Breath Tests ,inflammation ,1107 Immunology ,Family medicine ,General partnership ,Objective test ,business ,Biomarkers - Abstract
The diagnosis of asthma is currently based on clinical history, physical examination and lung function, and to date, there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state of the art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients. Using a two-stage e-Delphi process and a summarizing workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two-stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face-to-face workshop. The three most important diagnostic/predictive tools ranked were as follows: “New biological markers of asthma (eg genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring,” “Prediction of future asthma in preschool children with reasonable accuracy” and “Tools to measure volatile organic compounds (VOCs) in exhaled breath.”.
- Published
- 2018
18. Respiratory syncytial virus seasonality: A global overview
- Author
-
Obando-Pacheco, P. Justicia-Grande, A.J. Rivero-Calle, I. Rodríguez-Tenreiro, C. Sly, P. Ramilo, O. Mejías, A. Baraldi, E. Papadopoulos, N.G. Nair, H. Nunes, M.C. Kragten-Tabatabaie, L. Heikkinen, T. Greenough, A. Stein, R.T. Manzoni, P. Bont, L. Martinón-Torres, F.
- Subjects
viruses ,virus diseases ,respiratory system - Abstract
Respiratory syncytial virus (RSV) is the leading cause of acute lower respiratory infections in children. By the age of 1 year, 60%–70% of children have been infected by RSV. In addition, early-life RSV infection is associated with the development of recurrent wheezing and asthma in infancy and childhood. The need for precise epidemiologic data regarding RSV as a worldwide pathogen has been growing steadily as novel RSV therapeutics are reaching the final stages of development. To optimize the prevention, diagnosis, and treatment of RSV infection in a timely manner, knowledge about the differences in the timing of the RSV epidemics worldwide is needed. Previous analyses, based on literature reviews of individual reports obtained from medical databases, have failed to provide global country seasonality patterns. Until recently, only certain countries have been recording RSV incidence through their own surveillance systems. This analysis was based on national RSV surveillance reports and medical databases from 27 countries worldwide. This is the first study to use original-source, high-quality surveillance data to establish a global, robust, and homogeneous report on global country-specific RSV seasonality. © The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved.
- Published
- 2018
19. Gonadal function in human immunodeficiency virus (HIV)-infected men assessed by isotopic dilution-liquid chromatography-tandem mass spectrometry (ID-LC-MS/MS) and chemiluminescent assay
- Author
-
De Vincentis, S., Decaroli, M. C., Diazzi, C., Morini, F., Bertani, D., Fanelli, F., Mezzullo, M., Santi, D., Baraldi, E., Tagliavini, S., Pagotto, U., Guaraldi, G., and Rochira, Vincenzo
- Subjects
MALE HYPOGONADISM ,MASS SPECTROMETRY ,ANDROGENS ,ESTROGENS ,HIV ,SEX STEROIDS, ESTROGENS, ANDROGENS, GONADOTROPINS, HIV, MALE HYPOGONADISM, ID-LC-MS/MS, IMMUNOMETRY, MASS SPECTROMETRY ,SEX STEROIDS ,GONADOTROPINS ,ID-LC-MS/MS ,IMMUNOMETRY - Published
- 2018
20. Priorities for future research into asthma diagnostic tools: A PAN-EU consensus exercise from the European asthma research innovation partnership (EARIP)
- Author
-
Garcia-Marcos, L. Edwards, J. Kennington, E. Aurora, P. and Baraldi, E. Carraro, S. Gappa, M. Louis, R. and Moreno-Galdo, A. Peroni, D. G. Pijnenburg, M. Priftis, K. N. and Sanchez-Solis, M. Schuster, A. Walker, S. EARIP Collaboration
- Subjects
respiratory tract diseases - Abstract
The diagnosis of asthma is currently based on clinical history, physical examination and lung function, and to date, there are no accurate objective tests either to confirm the diagnosis or to discriminate between different types of asthma. This consensus exercise reviews the state of the art in asthma diagnosis to identify opportunities for future investment based on the likelihood of their successful development, potential for widespread adoption and their perceived impact on asthma patients. Using a two-stage e-Delphi process and a summarizing workshop, a group of European asthma experts including health professionals, researchers, people with asthma and industry representatives ranked the potential impact of research investment in each technique or tool for asthma diagnosis and monitoring. After a systematic review of the literature, 21 statements were extracted and were subject of the two-stage Delphi process. Eleven statements were scored 3 or more and were further discussed and ranked in a face-to-face workshop. The three most important diagnostic/predictive tools ranked were as follows: New biological markers of asthma (eg genomics, proteomics and metabolomics) as a tool for diagnosis and/or monitoring, Prediction of future asthma in preschool children with reasonable accuracy and Tools to measure volatile organic compounds (VOCs) in exhaled breath.
- Published
- 2018
21. La risposta degli steroidi allo stimolo con gonadotropina corionica (hCG) nei soggetti con sindrome di Klinefelter non cambia utilizzando gli immunodosaggi o la spettrometria di massa
- Author
-
Roli, L., Santi, D., Tagliavini, S., Cavalieri, S., De Santis, M. C., Baraldi, E., Fanelli, F., Mezzullo, M., Granata, A. R., Pagotto, U., Pasquali, R., Rochira, V., Carani, C., Simoni, M., and Trenti, T.
- Subjects
Immunoassay ,Klinefelter Syndrome ,Sex steroids ,hCG ,Androgens ,Testosterone ,Klinefelter Syndrome, Immunoassay, Mass Spectrometry, Sex steroids, Testosterone, Androgens, hCG ,Mass Spectrometry - Published
- 2018
22. Study of the molecular dialogue between grapevine inflorescence/berry and Botrytis cinerea during the initial, quiescent, and egression infection stages
- Author
-
Haile, Z.M., Pilati, S., Sonego, P., Malacarne, G., Vrhovsek, U., Engelen, K., Tudzynski, P., Zottini, M., Baraldi, E., and Moser, C.
- Subjects
Defence response ,Botrytis cinerea ,Vitis vinifera L ,Berries ,Flowers ,Quiescence ,Settore AGR/12 - PATOLOGIA VEGETALE - Published
- 2017
23. The burden of respiratory syncytial virus (RSV) associated acute lower respiratory infections in children with Down syndrome: A systematic review and meta-analysis
- Author
-
Chan, M. Park, J.J. Shi, T. Torres, F.M. Bont, L. Nair, H. Grobbee, D.E. Greenough, A. Manzoni, P. Papadopoulos, N. Baraldi, E. Falsey, A.R. Heikkinen, T. Mejías, A. Polack, F.P. Sharland, M. Ramilo, O. Stein, R.T. Martinón-Torres, F. Sly, P.D. Nunes, M. Respiratory Syncytial Virus Network (ReSViNET)
- Abstract
Background Acute lower respiratory tract infections (ALRIs) caused by respiratory syncytial virus (RSV) are a leading cause of hospitalization in infants. Numerous risk factors have been identified in the aetiology of severe RSV-associated ALRI necessitating hospitalisation, including prematurity and congenital heart disease. Down syndrome (DS), a common genetic disorder associated with congenital and dysmorphic features, has recently been identified as an independent risk factor for RSV-associated ALRI requiring hospitalisation; however, the disease burden of RSV-associated ALRI in this population has not yet been established. Similarly, the impact of DS as an independent risk factor has not yet been quantified. We aimed therefore to estimate the incidence of admissions in children with DS, and by comparing this with unaffected children, to quantify the risk of DS independent of other risk factors. Methods A systematic review of the existing literature published between 1995 and March 1, 2017 was performed to quantify the incidence of hospitalisation due to RSV-associated ALRI in children with DS. Meta-analyses were performed on extracted data using STATA statistical software, and hospitalisation rates for children with and without DS under the age of 2 were calculated. Findings 5 articles were ultimately deemed eligible for analyses. Analyses were limited to children under the age of 2 years. We calculated the hospitalisation rate for children with DS in this age group to be 117.6 per 1000 child-years (95% CI 67.4-205.2), vs a rate of 15.2 per 1000 child-years (95% CI 8.3-27.6) in unaffected children. This indicates DS contributes to a 6.8 (95% CI 5.5-8.4) fold increase in the relative risk of hospitalisation for RSV-associated ALRI. Interpretation Though limited by a small number of articles, this review found sufficient evidence to conclude DS was a significant independent risk factor for the development of severe RSV-associated ALRI requiring hospitalisation. Further studies are needed to define the impact of DS in conjunction with other comorbidities on the risk of severe RSV infection. Determining benefits of immunoprophylaxis or future vaccines against RSV in this at-risk population is warranted.
- Published
- 2017
24. LA METABOLOMICA APPLICATA AL WHEEZING RICORRENTE PRESCOLARE COME STRUMENTO PREDITTIVO DELLO SVILUPPO DI ASMA
- Author
-
Bozzetto, Sara, Mazzarolo, G., Giordano, G., Stocchero, M., Pirillo, P., Zanconato, S., Carraro, S., and Baraldi, E.
- Subjects
wheezing ricorrente ,metabolomica, wheezing ricorrente ,metabolomica - Published
- 2017
25. Environmental temperature and particulate matter are correlated with semen parameters: a big-data approach
- Author
-
Santi, Daniele, Magnani, E, Granata, Ar, Roli, L, De Santis MC, Baraldi, E, Trenti, T, Setti, M, and Simoni, M
- Published
- 2017
26. A european respiratory society technical standard: Exhaled biomarkers in lung disease
- Author
-
Horváth, I. Barnes, P.J. Loukides, S. Sterk, P.J. Högman, M. Olin, A.-C. Amann, A. Antus, B. Baraldi, E. Bikov, A. Boots, A.W. Bos, L.D. Brinkman, P. Bucca, C. Carpagnano, G.E. Corradi, M. Cristescu, S. De Jongste, J.C. Dinh-Xuan, A.-T. Dompeling, E. Fens, N. Fowler, S. Hohlfeld, J.M. Holz, O. Jöbsis, Q. De Kant, K.V. Knobel, H.H. Kostikas, K. Lehtimäki, L. Lundberg, J.O. Montuschi, P. Van Muylem, A. Pennazza, G. Reinhold, P. Ricciardolo, F.L.M. Rosias, P. Santonico, M. van der Schee, M.P. van Schooten, F.-J. Spanevello, A. Tonia, T. Vink, T.J.
- Subjects
respiratory tract diseases - Abstract
Breath tests cover the fraction of nitric oxide in expired gas (FENO), volatile organic compounds (VOCs), variables in exhaled breath condensate (EBC) and other measurements. For EBC and for FENO, official recommendations for standardised procedures are more than 10 years old and there is none for exhaled VOCs and particles. The aim of this document is to provide technical standards and recommendations for sample collection and analytic approaches and to highlight future research priorities in the field. For EBC and FENO, new developments and advances in technology have been evaluated in the current document. This report is not intended to provide clinical guidance on disease diagnosis and management. Clinicians and researchers with expertise in exhaled biomarkers were invited to participate. Published studies regarding methodology of breath tests were selected, discussed and evaluated in a consensus-based manner by the Task Force members. Recommendations for standardisation of sampling, analysing and reporting of data and suggestions for research to cover gaps in the evidence have been created and summarised. Application of breath biomarker measurement in a standardised manner will provide comparable results, thereby facilitating the potential use of these biomarkers in clinical practice. Copyright ©ERS 2017
- Published
- 2017
27. Meeting Report: Harmonization of RSV therapeutics - from design to performance
- Author
-
Nair, H, Ramilo, O, Eichler, I, Pelfrene, E, Mejias, A, Polack, FP, Pouwels, KB, Langley, JM, Nunes, M, van der Maas, N, Kragten-Tabatabaie, L, Baraldi, E, Heikkinen, T, Fauroux, B, Sharland, M, Park, C, Manzoni, P, Papadopoulos, NG, Martinon-Torres, F, Stein, R, Bont, L, and ReSV, RSVN
- Published
- 2016
28. Health consequences of obesity in children and adolescents
- Author
-
Valerio, G., Licenziati, M. R., Manco, M., Ambruzzi, A. M., Bacchini, D., Baraldi, E., Bona, Gianni, Bruzzi, P., Cerutti, F., Corciulo, N., Crinò, A., Franzese, A., Grugni, G., Iughetti, L., Lenta, S., Maffeis, C., Marzuillo, P., Miraglia Del Giudice, E., Morandi, A., Morino, G., Moro, B., Perrone, L., Flavia Prodam, Ricotti, Roberta, Santamaria, F., Zito, E., Tanas, R., Valerio, G, Licenziati, Mr, Manco, M, Ambruzzi, Am, Bacchini, Dario, Baraldi, E, Bona, G, Bruzzi, P, Cerutti, F, Corciulo, N, Crinò, A, Franzese, A, Grugni, G, Iughetti, L, Lenta, S, Maffeis, C, Marzuillo, P, MIRAGLIA DEL GIUDICE, Emanuele, Morandi, A, Morino, G, Moro, B, Perrone, Laura, Prodam, F, Ricotti, R, Santamaria, F, Zito, E, Tanas, R., Licenziati, M. R, Ambruzzi, A. M, Franzese, Adriana, Miraglia Del Giudice, E, and Perrone, L
- Subjects
Counseling ,obesity ,children ,morbidity ,Adolescent ,Health Status ,Respiratory Tract Diseases ,Body Mass Index ,Health Statu ,Diabetes Complications ,Risk Factors ,Behavior Therapy ,Cardiovascular Disease ,Diabetes Complication ,Weight Loss ,Prevalence ,Humans ,Musculoskeletal Diseases ,Obesity ,Child ,Life Style ,Respiratory Tract Disease ,Depression ,Risk Factor ,Overweight ,Weight Lo ,Italy ,Cardiovascular Diseases ,OBESITY ,Musculoskeletal Disease ,Insulin Resistance ,Human - Abstract
Obesity in childhood is associated with the presence of complications that can undermine health immediately or in the long term. Several conditions, such as pulmonary or orthopedic complications are strictly associated with the severity of overweight, since they are directly associated to the mechanic stress of fat tissue on the airways or on the bones. Other conditions, such as metabolic or liver complications, although increasing with the extent of overweight, are associated with insulin resistance, which can be modulated by different other factors (ethnicity, genetics, fat distribution) and can occur in overweight children as well. No less important are psychological correlates, such as depression and stigma, which can seriously affect the health related quality of life. Pediatric services for the care of childhood obesity need to be able to screen overweight and obese children for the presence of physical and psychological complications, which can be still reversed by weight loss. This article provides pediatricians a comprehensive update on the main complications in obese children and adolescents and their treatment.
- Published
- 2014
29. The influence of environment on the sperm quality: a comprehensive, retrospective, cohort study
- Author
-
Santi, Daniele, Vezzani, S, Roli L, Granata A., De Santis MC, Baraldi, E, Trenti, T, Setti, M, and Simoni, M.
- Published
- 2016
30. Meeting report: Harmonization of RSV therapeutics - from design to performance
- Author
-
Nair, H. Ramilo, O. Eichler, I. Pelfrene, E. Mejias, A. Polack, F.P. Pouwels, K.B. Langley, J.M. Nunes, M. van der Maas, N. Kragten-Tabatabaie, L. Baraldi, E. Heikkinen, T. Fauroux, B. Sharland, M. Park, C. Manzoni, P. Papadopoulos, N.G. Martinón-Torres, F. Stein, R. Bont, L. Respiratory Syncytial Virus Network (ReSViNET)
- Published
- 2016
31. International consensus on (ICON) pediatric asthma
- Author
-
Papadopoulos NG, Arakawa H, Carlsen KH, Custovic A, Gern J, Lemanske R, Le Souef P, Makela M, Roberts G, Wong G, Zar H, Akdis CA, Bacharier LB, Baraldi E, van Bever HP, de Blic J, Boner A, Burks W, Casale TB, Castro-Rodriguez JA, Chen YZ, El-Gamal YM, Everard ML, Frischer T, and Geller M
- Published
- 2012
32. Assessment of problematic severe asthma in children
- Author
-
Carlsen, K. C. L., Hedlin, G., Bush, A., Wennergren, G., de Benedictis, F. M., De Jongste, J. C., Baraldi, E., Pedroletti, C., Barbato, A., Malmstrom, K., Pohunek, P., Pedersen, S., Piacentini, G. L., Middelveld, R. J. M., Carlsen, K. H., Grp, Psaci, and Pediatrics
- Subjects
Pulmonary and Respiratory Medicine ,Severe asthma ,medicine.medical_specialty ,diagnosis ,Comorbidity ,Severity of Illness Index ,children ,Treatment plan ,medicine ,Humans ,Anti-Asthmatic Agents ,Child ,Intensive care medicine ,Rhinitis ,Asthma ,business.industry ,medicine.disease ,Respiratory Function Tests ,Clinical Practice ,Treatment Outcome ,Lung disease ,Physical therapy ,Bronchial Hyperreactivity ,business - Abstract
Assessment of problematic severe asthma in children should be performed in a step-wise manner to ensure an optimal approach. A four-step assessment scheme is proposed. First, a full diagnostic work-up is performed to exclude other diseases which mimic asthma. Secondly, a multi-disciplinary assessment is performed to identify issues that may need attention, including comorbidities. Thirdly, the pattern of inflammation is assessed, and finally steroid responsiveness is documented. Based upon these four steps an optimal individualised treatment plan is developed. In this article the many gaps in our current knowledge in all these steps are highlighted, and recommendations for current clinical practice and future research are made. The lack of good data and the heterogeneity of problematic severe asthma still limit our ability to optimise the management on an individual basis in this small, but challenging group of patients.
- Published
- 2011
33. Regular vs prn nebulized treatment in wheeze preschool children
- Author
-
Papi, A., Nicolini, G., Baraldi, E., Boner, A. L., Cutrera, R., Rossi, G. A., Fabbri, Leonardo, and BEclomethasone Study Group, B.
- Subjects
Male ,Exacerbation ,Salbutamol ,As needed ,Asthma ,Beclomethasone ,Wheezing ,law.invention ,administration /&/ dosage/therapeutic use ,Randomized controlled trial ,law ,Bronchodilator ,Immunology and Allergy ,Medicine ,Anti-Asthmatic Agents ,Child ,Bronchodilator Agents ,Treatment Outcome ,Inhalation ,Child, Preschool ,Anesthesia ,Administration ,Combination ,Inhalation, Albuterol ,administration /&/ dosage/therapeutic use, Anti-Asthmatic Agents ,administration /&/ dosage/therapeutic use, Asthma ,drug therapy/physiopathology, Beclomethasone ,administration /&/ dosage/therapeutic use, Bronchodilator Agents ,administration /&/ dosage/therapeutic use, Child ,Preschool, Double-Blind Method, Drug Administration Schedule, Drug Therapy ,Combination, Female, Glucocorticoids ,administration /&/ dosage/therapeutic use, Humans, Infant, Male, Nebulizers and Vaporizers, Respiratory Sounds ,drug effects, Treatment Outcome ,Drug Therapy, Combination ,Female ,medicine.symptom ,Glucocorticoid ,medicine.drug ,medicine.medical_specialty ,medicine.drug_class ,Immunology ,Placebo ,Drug Administration Schedule ,Double-Blind Method ,Drug Therapy ,Wheeze ,Internal medicine ,Administration, Inhalation ,Humans ,Albuterol ,Preschool ,Glucocorticoids ,Respiratory Sounds ,business.industry ,Nebulizers and Vaporizers ,Infant ,drug therapy/physiopathology ,medicine.disease ,drug effects ,business - Abstract
Background: International guidelines recommend regular treatment with inhaled glucocorticoids for children with frequent wheezing; however, prn inhaled bronchodilator alone or in combination with glucocorticoid is also often used in practice. We aimed to evaluate whether regular nebulized glucocorticoid plus a prn bronchodilator or a prn nebulized bronchodilator/glucocorticoid combination is more effective than prn bronchodilator alone in preschool children with frequent wheeze. Methods: Double-blind, double-dummy, randomized, parallel-group trial. After a 2-week run-in period, 276 symptomatic children with frequent wheeze, aged 1–4 years, were randomly assigned to three groups for a 3-month nebulized treatment: (1) 400 μg beclomethasone bid plus 2500 μg salbutamol prn; (2) placebo bid plus 800 μg beclomethasone/1600 μg salbutamol combination prn; (3) placebo bid plus 2500 μg salbutamol prn. The percentage of symptom-free days was the primary outcome measure. Secondary outcomes included symptom scores, use of relief medication and exacerbation frequency. Results: As compared with prn salbutamol (61.0 ± 24.83 [SD]), the percentage of symptom-free days was higher with regular beclomethasone (69.6%, SD 20.89; P = 0.034) but not with prn combination (64.9%, SD 24.74). Results were no different in children with or without risk factors for developing persistent asthma. The effect of prn combination was no different from that of regular beclomethasone on the primary and on several important secondary outcomes. Conclusions: Regular inhaled glucocorticoid is the most effective treatment for frequent wheezing in preschool children. However, prn bronchodilator/glucocorticoid combination might be an alternative option, but it requires further study.
- Published
- 2009
34. Monitoring asthma in children
- Author
-
Pijnenburg, M W, Baraldi, E, et al, Moeller, A, University of Zurich, and Pijnenburg, M W
- Subjects
10036 Medical Clinic ,2740 Pulmonary and Respiratory Medicine ,610 Medicine & health - Published
- 2015
35. RNA seq analysis of unripe and ripe strawberry fruits interacting with Botrytis cinerea
- Author
-
Zoli, L., Sonego, P., Moretto, M., Engelen, K.A., Tudzynski, P., Moser, C., and Baraldi, E.
- Subjects
Botrytis cinerea ,Botrite ,RNA-Seq ,Settore AGR/12 - PATOLOGIA VEGETALE ,Strawberry ,Fragola - Published
- 2015
36. Antibiotic research and development: business as usual?
- Author
-
Harbarth, S, Theuretzbacher, U, Hackett, J, collaborators: Adriaenssens, N, Anderson, J, Antonisse, A, Årdal, C, Baillon-Plot, N, Baraldi, E, Bettiol, E, Bhatti, T, Bradshaw, D, Brown, N, Carmeli, Y, Cars, O, Charbonneau, C, Cheng, S, Ciabuschi, F, Cirino, J, Clift, C, Colson, A, Dane, A, De-Lima, N, Dooa, M, Drabik, D, Eisenstein, B, Farquhar, R, Fidan, D, Findlay, D, Galli, F, Gilchrist, K, Gilman, S, Goeschl, T, Goodall, J, Goossens, H, Gouglas, D, Guise, T, Gyssens, I, Hallerbäck, P, Heymann, D, Hoffman, S, Howell, J, Hulscher, M, Hunt, T, Huttner, B, Jantarada, F, Jaquest, D, Joly, F, Ka, L, Karas, A, Knirsch, C, Kullberg, Bj, Laxminarayan, R, Le Maréchal, M, Legros, S, Lilliott, N, Lindgren, E, Longshaw, C, Mahoney, N, Mastrangelo, D, Mcdonald, J, Mckeever, S, Mepham, T, Milanic, R, Monnier, A, Morel, C, Morton, A, Mossialos, E, Nolet, B, Outterson, K, Payne, D, Piddock, L, Plahte, J, Potter, D, Pulcini, C, Rex, J, Ross, E, Rottingen, Ja, Ryan, K, Ryan, J, Salimi, T, Schouten, J, Schultz, S, So, A, Spiesser, J, Stålhammar, No, Stanic, M, Tacconelli, E, Temkin, L, Trick, D, Vink, P, Vlahovic-Palcevski, V, Watt, M, Wells, M, Wesseler, J, White, A, Wood, S, Zanichelli, V, and Zorzet, A.
- Subjects
Microbiology (medical) ,antimicrobial agents ,clinical studies ,drug development ,economics ,global health policy ,multidrug resistance ,patient safety ,Anti-Bacterial Agents ,Drug Discovery ,Drug Industry ,Humans ,Motivation ,Research ,medicine.drug_class ,Economic policy ,Economics ,Antibiotics ,WASS ,Drug development ,Multidrug resistance ,Patient safety ,Antibiotic resistance ,medicine ,Agricultural Economics and Rural Policy ,Pharmacology (medical) ,Pharmacology ,ddc:616 ,Agrarische Economie en Plattelandsbeleid ,Investment (macroeconomics) ,Antimicrobial agents ,Infectious Diseases ,Incentive ,lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4] ,Economic model ,Business ,Anti-Infective Agents ,Clinical studies ,Global health policy - Abstract
The global burden of antibiotic resistance is tremendous and, without new anti-infective strategies, will continue to increase in the coming decades. Despite the growing need for new antibiotics, few pharmaceutical companies today retain active antibacterial drug discovery programmes. One reason is that it is scientifically challenging to discover new antibiotics that are active against the antibiotic-resistant bacteria of current clinical concern. However, the main hurdle is diminishing economic incentives. Increased global calls to minimize the overuse of antibiotics, the cost of meeting regulatory requirements and the low prices of currently marketed antibiotics are strong deterrents to antibacterial drug development programmes. New economic models that create incentives for the discovery of new antibiotics and yet reconcile these incentives with responsible antibiotic use are long overdue. DRIVE-AB is a €9.4 million public–private consortium, funded by the EU Innovative Medicines Initiative, that aims to define a standard for the responsible use of antibiotics and to develop, test and recommend new economic models to incentivize investment in producing new anti-infective agents.
- Published
- 2015
37. Lower respiratory tract infection caused by respiratory syncytial virus: Current management and new therapeutics
- Author
-
Mazur, N.I. Martinón-Torres, F. Baraldi, E. Fauroux, B. Greenough, A. Heikkinen, T. Manzoni, P. Mejias, A. Nair, H. Papadopoulos, N.G. Polack, F.P. Ramilo, O. Sharland, M. Stein, R. Madhi, S.A. Bont, L. Respiratory Syncytial Virus Network (ReSViNET)
- Abstract
Respiratory syncytial virus (RSV) is a major worldwide cause of morbidity and mortality in children under five years of age. Evidence-based management guidelines suggest that there is no effective treatment for RSV lower respiratory tract infection (LRTI) and that supportive care, ie, hydration and oxygenation, remains the cornerstone of clinical management. However, RSV treatments in development in the past decade include 10 vaccines and 11 therapeutic agents in active clinical trials. Maternal vaccination is particularly relevant because the most severe disease occurs within the first 6 months of life, when children are unlikely to benefit from active immunisation. We must optimise the implementation of novel RSV therapeutics by understanding the target populations, showing safety, and striving for acceptable pricing in the context of this worldwide health problem. In this Review, we outline the limitations of RSV LRTI management, the drugs in development, and the remaining challenges related to study design, regulatory approval, and implementation. © 2015 Elsevier Ltd.
- Published
- 2015
38. Botrytis cinerea and grapevine inflorescence interaction
- Author
-
Haile, Z.M., Sonego, P., Engelen, K.A., Tudzinsky, P., Baraldi, E., and Moser, C.
- Subjects
Settore AGR/12 - PATOLOGIA VEGETALE - Published
- 2015
39. DIFETTO DI LINFOCITI Ccr4/Ccr6+ IN PAZIENTI CON SINDROME DI IPER IgE CORRELA CON RIDUZIONE DEI LINFOCITI Th17
- Author
-
Guadrini L, Giacomelli M, Moratto M, Caracciolo S, Nigro S, Lougaris V, Pajno G, Porta F. Salpietro A, Monfredini C, Corrente S, Soresina A, Aiuti A, Cancrini C, Ragusa G, Gallizzi R, Tommasini A, Montin D, Specchia G. G, Baraldi E, Nespoli L, Duse M, Plebani A, Badolato R., RICCI, GIAMPAOLO, Guadrini L, Giacomelli M, Moratto M, Caracciolo S, Nigro S, Lougaris V, Pajno G, Porta F. Salpietro A, Monfredini C, Corrente S, Soresina A, Aiuti A, Cancrini C, Ragusa G, Gallizzi R, Tommasini A, Montin D, Ricci G, Specchia G.G, Baraldi E, Nespoli L, Duse M, Plebani A, and Badolato R
- Subjects
SINDROME DA IPER IGE ,LINFOCITI TH17 - Published
- 2012
40. RSV-still more questions than answers
- Author
-
Bont, L. Baraldi, E. Fauroux, B. Greenough, A. Heikkinen, T. Manzoni, P. Martinón-Torres, F. Nair, H. Papadopoulos, N.G.
- Published
- 2014
41. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma
- Author
-
de Jongste JC, Carraro, S, Hop, Wc, CHARISM Study Group, Aanstoot, Hj, Baraldi, E, Boner, Attilio, Carraro, S., de Benedictis, F. M., Feith, S. W., de Jongste, J. C., Greijn, M. H., Landi, L., Marseglia, G., Novembre, E., Pescollderung, L., Rossi, G., Schornagel, R., Verberne, A., van Veen, L. N., Baraldi, E., Pediatrics, and Epidemiology
- Subjects
Pulmonary and Respiratory Medicine ,Budesonide ,Male ,medicine.medical_specialty ,Adolescent ,Monitoring, Ambulatory ,Critical Care and Intensive Care Medicine ,Nitric Oxide ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Administration, Inhalation ,medicine ,Clinical endpoint ,Humans ,Prospective Studies ,Prospective cohort study ,Child ,Glucocorticoids ,Asthma ,Netherlands ,Inhalation ,business.industry ,Airway inflammation • inhaled corticosteroid • symptom-free days • lung function • telemedicine ,medicine.disease ,Treatment Outcome ,Breath Tests ,Patient Satisfaction ,Anesthesia ,Exhaled nitric oxide ,Ambulatory ,Quality of Life ,Feasibility Studies ,Female ,business ,Biomarkers ,medicine.drug - Abstract
Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FeNO0.05), a marker of eosinophilic airway inflammation, can be measured at home.We assessed daily FeNO0.05 telemonitoring in the management of childhood asthma.Children with atopic asthma (n = 151) were randomly assigned to two groups: FeNO0.05 plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FeNO0.05 and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks.Telemonitoring was feasible with reliable FeNO0.05 data for 86% of days, and valid diary entries for 79% of days. Both groups showed an increase in symptom-free days, improvement of FEV1 and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weeks was 0.3% (P = 0.95; 95% confidence interval, -10 to 11%). There was a trend for fewer exacerbations in the FeNO0.05 group.Thirty weeks of daily FeNO0.05 and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FeNO0.05 monitoring compared with daily symptom monitoring only.
- Published
- 2008
42. Chronic lung disease after premature birth
- Author
-
CUTZ E, CHIASSON D, KIREN V, BARBI E, FILIPPONE M, BARALDI E., VENTURA, ALESSANDRO, Cutz, E, Chiasson, D, Kiren, V, Barbi, E, Ventura, Alessandro, Filippone, M, and Baraldi, E.
- Published
- 2008
43. Nanotechnology and central nervous system drug delivery
- Author
-
Tosi, G., Ruozi, B., Vilella, A., Belletti, D., Veratti, P., Baraldi, E., Zoli, M., Grabrucker, A., Sharma, A., Sharma, H. S., Flavio Forni, and Vandelli, M.
- Subjects
drug delivery ,Nanoparticles ,central nervous system - Published
- 2013
44. The commercialization of science as an embedding process : The case of PET radiotracers at Uppsala University
- Author
-
Baraldi, E. and Launberg, Anna
- Subjects
Business Administration ,Företagsekonomi - Abstract
This paper discusses the commercialization of science as an embedding process within a complex network of technical and social resources resources. We rely on a single in-depth case study over the commercialization and de-commercialization of Uppsala PET center in order to identify how PET radiotracers, our focal piece of science, are interfaced with other resources and how they are connected to the three settings of developing, producing and using. We find that the twists and turns in the innovation journey of the PET center depend on deep technical interfaces, problematic mixed interfaces that create conflicts between the involved actors, and shallow organizational interfaces
- Published
- 2013
45. Measurement of exhaled nitric oxide in children, 2001.European Respiratory Society/American Thoracic Society (ERS/ATS) Task Force.PMID: 12166573
- Author
-
Baraldi, E, de Jongste JC, Baraldi E, European Respiratory Society/American Thoracic Society Task F. o. r. c. e., Gaston, B, Alving, K, Barnes, Pj, Bisgaard, H, Bush, A, Gaultier, C, Grasemann, H, Hunt, Jf, Kissoon, N, Piacentini, Giorgio, Ratjen, F, Silkoff, P, and Stick, S.
- Subjects
exhaled air ,Fractional exhaled nitric oxide ,asthma - Published
- 2002
46. Insights on the molecular mechanisms regulating the anti-botrytis activity of VvAMP-13, a defensin from grapevine
- Author
-
Nanni, V., Schumacher, J., Sbolci, L., Brazzale, D., Bertolini, P., Tudzynski, P., Moser, C., and Baraldi, E.
- Subjects
Defensins ,Defensine ,Vite ,Grapevine ,Botrite ,Botrytis ,Settore AGR/12 - PATOLOGIA VEGETALE - Published
- 2012
47. International consensus on (ICON) pediatric asthma
- Author
-
Papadopoulos, N.G. Arakawa, H. Carlsen, K.-H. Custovic, A. Gern, J. Lemanske, R. Le Souef, P. Mäkelä, M. Roberts, G. Wong, G. Zar, H. Akdis, C.A. Bacharier, L.B. Baraldi, E. Van Bever, H.P. De Blic, J. Boner, A. Burks, W. Casale, T.B. Castro-Rodriguez, J.A. Chen, Y.Z. El-Gamal, Y.M. Everard, M.L. Frischer, T. Geller, M. Gereda, J. Goh, D.Y. Guilbert, T.W. Hedlin, G. Heymann, P.W. Hong, S.J. Hossny, E.M. Huang, J.L. Jackson, D.J. De Jongste, J.C. Kalayci, O. Aït-Khaled, N. Kling, S. Kuna, P. Lau, S. Ledford, D.K. Lee, S.I. Liu, A.H. Lockey, R.F. Lãdrup-Carlsen, K. Lötvall, J. Morikawa, A. Nieto, A. Paramesh, H. Pawankar, R. Pohunek, P. Pongracic, J. Price, D. Robertson, C. Rosario, N. Rossenwasser, L.J. Sly, P.D. Stein, R. Stick, S. Szefler, S. Taussig, L.M. Valovirta, E. Vichyanond, P. Wallace, D. Weinberg, E. Wennergren, G. Wildhaber, J. Zeiger, R.S.
- Abstract
Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved. © 2012 John Wiley & Sons A/S.
- Published
- 2012
48. Asymmetric dimethylarginine (ADMA) in EBC of asthmatic children
- Author
-
Carraro, S, Di Gangi IM, Piacentini, Giorgio, Kantar, A, Moser S, Cesca L, Berardi, M, Giordano, G, and Baraldi, E.
- Subjects
ADMA ,children ,asthma - Published
- 2012
49. Gene expression, antimicrobial activity and membrane interaction of the peach defensin PpDFN1
- Author
-
Nanni, V., Zanetti, M., Dalla Serra, M., Moser, C., Bertolini, P., and Baraldi, E.
- Published
- 2011
50. Identification and characterization of the grapevine defensin-like gene family
- Author
-
Giacomelli, L., Nanni, V., Silverstein, K., Town, C., Zanetti, M., Lenzi, L., Baraldi, E., Dalla Serra, M., and Moser, C.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.